KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have B-cell acute lymphoblastic leukemia that has come back after treatment or hasn't responded to standard chemotherapy.
- Your cancer cells carry a protein called CD19, as shown by a recent bone marrow or blood test.
- You are otherwise relatively healthy, able to do daily activities, and have adequate organ function (like kidney, liver, and heart).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use effective birth control for at least one year after treatment.
- You have not received certain other cancer treatments (like specific chemotherapy, immunotherapy, or radiation) within a certain timeframe before joining the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called JY231 for people with a type of blood cancer (B-cell leukemia) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.